Noradrenaline Sans Conservateur Renaudin (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a potent vasopressor in critical‑care settings, targeting severe hypotensive states.

• Hypotension: restores vascular tone and raises arterial pressure in acute low‑blood‑pressure states.
• Septic shock: counteracts profound vasodilation and supports organ perfusion in septic patients.
• Vasodilatory shock: provides vasoconstriction to improve systemic vascular resistance when other agents are insufficient.

• Noradrenaline tartrate directly stimulates alpha‑1 and alpha‑2 adrenergic receptors on vascular smooth muscle, producing vasoconstriction and increasing systemic vascular resistance. The resultant rise in arterial pressure improves perfusion to vital organs, while alpha‑2 activation also reduces norepinephrine release, contributing to its overall hemodynamic effect.

Adverse reactions may vary with dose and patient condition.

Common Side Effects

• Headache: mild to moderate pain often related to rapid blood‑pressure changes.
• Tachycardia: increased heart rate due to reflex mechanisms.
• Arrhythmia: irregular heart rhythms, especially at high infusion rates.
• Hypertension: excessive rise in blood pressure if over‑titrated.
• Peripheral ischemia: reduced blood flow to extremities causing coldness or discoloration.
• Nausea: gastrointestinal discomfort reported in some patients.

Serious or Rare Side Effects

• Myocardial ischemia: reduced coronary blood flow leading to chest pain or infarction.
• Severe hypertension: dangerously high blood pressure that may cause vascular injury.
• Tissue necrosis at infusion site: local tissue death if extravasation occurs.
• Life‑threatening arrhythmias: ventricular tachycardia or fibrillation.
• Pulmonary edema: fluid accumulation in lungs due to abrupt hemodynamic shifts.

When using noradrenaline, careful monitoring and specific precautions are essential.

• Dose titration: adjust infusion rate to achieve target mean arterial pressure while avoiding overshoot.
• Cardiac monitoring: continuously observe ECG for arrhythmias or ischemic changes.
• Peripheral perfusion: inspect infusion sites regularly for signs of ischemia or extravasation.
• Pregnancy and lactation: use only if potential benefits justify potential risks to the fetus or infant.
• Concomitant MAO inhibitors: avoid because of heightened risk of hypertensive crisis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze, and use within the labeled shelf‑life.

Noradrenaline may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

• MAO inhibitors: can precipitate severe hypertension.
• Beta‑blockers: may blunt the expected tachycardic response.
• Tricyclic antidepressants: additive vasoconstrictive effect increasing blood‑pressure risk.

Moderate Interactions (Monitor Closely)

• Vasodilators (e.g., nitroglycerin): may necessitate higher noradrenaline doses.
• Calcium channel blockers: can increase the likelihood of bradycardia when combined.
• Inhaled anesthetics: may potentiate hypotensive effects, requiring dose adjustments.